Michael D. Crowther

Heath Park
Cardiff, WLS, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.

Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.

Journal: Signal transduction and targeted therapy

Published: February 20, 2026

Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

Journal: The Lancet. Oncology

Published: May 03, 2025

Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease.

Transvitreal Retinochoroidal Biopsies of Primary Uveal Melanoma Reveal an Association of Low HLA Class I and High NK Cell Abundance in Low-Risk Disease.

Journal: Investigative ophthalmology & visual science

Published: February 07, 2025

MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.

MHC-related protein 1-restricted recognition of cancer via a semi-invariant TCR-α chain.

Journal: The Journal of clinical investigation

Published: April 11, 2024

Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.

Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 21, 2022

Ligand Identification for Orphan MHC-Agnostic T-Cell Receptors by Whole Genome CRISPR-Cas9 Screening.

Ligand Identification for Orphan MHC-Agnostic T-Cell Receptors by Whole Genome CRISPR-Cas9 Screening.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: September 10, 2022

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.

Journal: Cell

Published: July 17, 2022

Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.

Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.

Journal: Cancer immunology research

Published: April 22, 2022

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.

Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.

Journal: The Journal of clinical investigation

Published: May 04, 2021

The burgeoning role of MR1-restricted T-cells in infection, cancer and autoimmune disease.

The burgeoning role of MR1-restricted T-cells in infection, cancer and autoimmune disease.

Journal: Current opinion in immunology

Published: July 16, 2020

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Journal: Cells

Published: May 22, 2020

Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.

Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.

Journal: Nature immunology

Published: March 04, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026